University of Sussex
Browse

File(s) not publicly available

Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease

journal contribution
posted on 2023-06-08, 12:32 authored by Lesley FallowfieldLesley Fallowfield, Roger Von Moos, Luis Costa, Aliston Stopeck, Mark Clemons, Noel Clarke, Ada Braun, Karen Chung
The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients’ lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously. These data, when considered alongside various patient characteristics, can provide oncologists with better opportunities to individualise care. Optimal management with treatments that enhance efficacy and adherence mean that clinicians can improve the outlook for their patients with MBD, who may consequently experience fewer SREs and less pain and enjoy a better overall quality of life.

History

Publication status

  • Published

Journal

European Oncology & Haematology

ISSN

1578-3853

Publisher

Touch Briefings

Issue

3

Volume

8

Page range

148-155

Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2012-10-05

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC